For example, mutations of KRAS and NRAS predict resistance to anti-EGFR antibodies in colorectal cancers, and patients with lung adenocarcinoma that harbor EGFR mutations or ALK rearrangements have shown remarkable efficacy in relevant targeted drug therapy (21, 22). Here, EGFR is linked to lung adenocarcinoma.